Med Life SA · BVB:M
Med Life SA — FY2021 Earnings Presentation
18 slides from Med Life SA's earnings presentation, March 2022
Slide 1: Preliminary Financial Results 2021
Preliminary Financial Results 2021 Divizia Spitale Strategie de comunicare 2022 www.medlife.ro
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: Agenda
1 • Snapshot Highlights 12m 2021 • Key messages 12m 2021 • Outlook AGENDA Financial overview • Consolidated Statement of Profit and Loss 2 • • Consolidated Statement of Financial Position Consolidated Statement of Cash Flow Q&A Session 3 3/
Slide 4: Highlights 12m 2021
Highlights 12m 2021 • Snapshot • Key messages 12m 2021 • Outlook 1 4/
Slide 5: Snapshot
Snapshot ➢ Pro-forma consolidated Sales of RON 1.6 bn in 2021, increased by 51.6% compared to 2020; ➢ IFRS consolidated Sales of RON 1.4 bn in 2021 , increased by 32.9% compared to 2020 (24% like to like increase); ➢ Strong operating performance, in line with the strategy of recent years; ➢ 20.1% IF
Slide 6: Key messages 12m 2021
Key messages 12m 2021 - In 2021, MedLife Group continued its dynamic strategy of expansion through acquisitions; - The Group consolidated its profitability margins despite yet a still pandemic environment; - Investments were directed towards supporting strategic objectives aimed at research, strengt
Slide 7: Key messages 12m 2021
Key messages 12m 2021 - the research area has played an important role during 2021, aggregating investments of over 1 million euros; - 2021 also marked the consolidation of the oncology services segment after the Group has recently received the Competition Council approval for the acquisition of 50%
Slide 8: Operational KPIs – supporting annex for BL evolution and bridge to pro-forma figures
Operational KPIs – supporting annex for BL evolution and bridge to pro-forma figures On a pro-forma basis, Clinics remain the main sales unit of the group, with 27% share of total pro-forma consolidated Sales, followed by Hospitals with 24% (which also reflect NeoLife acquisition) and Laboratories w
Slide 9: Outlook for 2022 and onwards
Outlook for 2022 and onwards ➢ Ongoing discussions with 3 large and medium-sized companies, but also with 5 other small companies to join the group and aims that most of these discussions will materialize this year; ➢ The investment budget planned for the next period is 100-120 million euros, approx
Slide 10: Outlook for 2022 and onwards
Outlook for 2022 and onwards ➢ 2022 goals are also linked to MedLife Park, which entered its second phase of development. We plan on launching a new state of the art Hyperclinic and expanding the laboratory of molecular biology and pathological anatomy. The company aims for a much larger unit to acc
Slide 11: Financial overview
Financial overview Consolidated Stetement of Profit and Loss Consolidated Statement of Financial Position Consolidated Stetement of Cash Flow 2 11 /
Slide 12: Consolidated Statement of Profit and Loss (1/3)
Consolidated Statement of Profit and Loss (1/3) 12 / 1.Highlights 2021 2. Financial overview 3. Q&A Session
Slide 13: Consolidated Statement of Profit and Loss (2/3)
Consolidated Statement of Profit and Loss (2/3) explained 1) 12m 2021 Pro-forma vs. 12m 2020 IFRS ❑ Sales increased by 51.6%, to RON 1.6 bn; ❑ OPEX increased by 49.4%, to RON 1.4 bn; ❑ 71.6% increase in EBIT, to 187m RON, leading to 11.5% pro-forma margin (10.1% in the same period last year) ❑ EBITD
Slide 14: Consolidated Statement of Profit and Loss (3/3)
Consolidated Statement of Profit and Loss (3/3) OPEX Evolution Release of 1.1 p.p. in EBITDA margin due to: ➢ Decrease in Consumable materials and repair materials with 1.3 p.p. of Sales due to decreased trend on PCR testing and Pharmachem consolidation; ➢ Increase in Commodities with 4.1 p.p. of Sa
Slide 15: Consolidated Statement of Financial Position (1/2)
Consolidated Statement of Financial Position (1/2) 15 / 1.Highlights 2021 2. Financial overview 3. Q&A Session
Slide 16: Consolidated Statement of Financial Position (2/2)
Consolidated Statement of Financial Position (2/2) Debt position 16 / 1.Highlights 2021 2. Financial overview 3. Q&A Session
Slide 17: Consolidated Statement of Cash Flow
Consolidated Statement of Cash Flow Cash flow for the period characterized by increased operating performance: 1. 1.7 times increase in net cash from operating activities, to 214m RON; 2. 30% increase in investments YoY, to 146m RON; 3. Net repayment in financing activities of 19m RON 17 / 1.Highlig
Slide 18: Q&A Session - Thank you!
Q&A Session Thank you! 3 18 /